glycyl-arginyl-glycyl-aspartyl-serine has been researched along with perfluoropentane in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-serine) | Trials (glycyl-arginyl-glycyl-aspartyl-serine) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-serine) | Studies (perfluoropentane) | Trials (perfluoropentane) | Recent Studies (post-2010) (perfluoropentane) |
|---|---|---|---|---|---|
| 190 | 0 | 42 | 176 | 12 | 106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, L; Liu, M; Liu, Y; Sheng, D; Song, J; Wang, Z; Wu, M; Yang, Z; Yi, H; Zhang, L; Zhang, N; Zheng, Y | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-serine and perfluoropentane
| Article | Year |
|---|---|
Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Drug Delivery Systems; Female; Fluorocarbons; Immunotherapy; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanoparticles; Oligopeptides; Phototherapy; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2019 |